Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen

J Neuroimmunol. 2012 Mar;244(1-2):35-44. doi: 10.1016/j.jneuroim.2011.12.024. Epub 2012 Jan 14.

Abstract

Immune-mediated diseases [multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE)] are driven by proliferating, highly activated autoreactive T-cells that are unresponsive to in vivo immunoregulatory mechanisms. The compound Lenaldekar (LDK) was identified in a zebrafish screen by inhibiting T-cell expansion. By monitoring mitogen- and antigen-driven proliferation, we found that LDK inhibited human and murine T-cell expansion in a non-cytolytic manner. This suppressive activity directly correlated with the degree of activation/proliferation of the T-cells. In testing LDK in an EAE model of MS, exacerbations were suppressed in treated animals. Therefore, LDK represents a novel therapeutic approach to T-cell-mediated autoimmune diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Female
  • Humans
  • Hydrazones / therapeutic use*
  • Lymphocyte Activation / drug effects*
  • Mice
  • Multiple Sclerosis / drug therapy*
  • Quinolines / therapeutic use*
  • Small Molecule Libraries
  • T-Lymphocytes / drug effects*
  • Zebrafish

Substances

  • 1H-indole-3-carbaldehyde quinolin-8-yl-hydrazone
  • Hydrazones
  • Quinolines
  • Small Molecule Libraries